Heteroaryl alkyl piperazine derivatives as fatty acid oxidation inhibitors
Details for Australian Patent Application No. 2002255466 (hide)
International Classifications
Event Publications
20 February 2003 Application Open to Public Inspection
Published as AU-B-2002255466
15 July 2004 Application Accepted
Published as AU-B-2002255466
11 November 2004 Standard Patent Sealed
15 October 2009 Amendment Made
The nature of the amendment is: Amend the patentee name from CV Therapeutics, Inc. to Gilead Palo Alto, Inc.
12 May 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired
This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.
Legal
The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.
Next and Previous Patents/Applications
IP Reporting Samples
Customised IP Reporting
IP Insider for IP Professionals
IP Monitor Professional
- Editable Word format reports
- For IP Professionals
- Multiuser